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8.1
CHANGES IN DYNAMIC CONTRAST-ENHANCED MRI AS 
AN EARLY PREDICTOR OF RESPONSE TO NEOADJUVANT 
CHEMOTHERAPY IN PRIMARY BREAST CANCER
MW Ah-See 1, A Makris 1, NJ Taylor 1, M Harrison 1, PJ Ostler 1,
PI Richman 1, JJ Stirling 1, RJ Burcombe 1, MO Leach 2, MR Pittam 3, 
D Ravichandran 3, JA D’Arcy 2, AR Padhani 1
1 Mount Vernon Hospital, Northwood, United Kingdom, 2 Royal 
Marsden Hospital, Sutton, United Kingdom, 3 Luton & Dunstable 
Hospital, Luton, United Kingdom
Background: The ability to identify early during treatment those women 
with primary breast cancer (PBC) who will fail to respond to neoadjuvant 
chemotherapy (NAC) will enable the use of alternative therapies that may 
be more effective. Here, we assess the role of dynamic contrast-enhanced 
MRI (DCE-MRI) to identify the non-responders. Methods: 28 patients with 
PBC (median age 46 years; range 29-70) were imaged prior to & following 2 
cycles of 5-ﬂ  uorouracil, epirubicin & cyclophosphamide NAC. DCE-MRI was 
performed using gadolinium & parametric images were calculated reﬂ  ecting 
tissue microvessel permeability, leakage space & perfusion (Ktrans, ve, kep, 
MaxGd, rBV , rBF & MTT). Median & 5-95th centile values for each parameter 
were derived from whole tumour regions of interest. Pre-treatment parameter 
values & treatment changes were correlated with clinical & pathological 
response following 6 cycles of NAC using the Mann-Whitney U-test. A cohort 
of 9 patients was imaged twice prior to therapy to calculate the repeatability 
statistic for each parameter & hence determine the ability of DCE-MRI to 
predict pathological non-response on a patient-by-patient basis. 
Results: Clinically there were 19 responders & 9 non-responders; pathologically 
there were 11 responders & 17 non-responders. Pre-treatment parameter values 
& change in tumour size did not predict for response. Group analysis showed 
that changes in median Ktrans, kep, rBV & rBF correlated with both ﬁ  nal clinical & 
pathological response to NAC (p<0.01) as did changes in 5-95th centile range for 
these parameters (p<0.05). Application of the repeatability statistic revealed change 
in median Ktrans to be the best predictor of pathological non-response in individuals 
(repeatability range -49 to 97%) correctly predicting pathological non-response in 
all 17 patients (100%) & response in 6/11 patients (55%). Conclusion: Patients 
who are destined to fail to respond to NAC can be identiﬁ  ed from early changes in 
DCE-MRI parameters that reﬂ  ect on microvessel perfusion & permeability.
8.2
UNEXPECTED UPREGULATION OF MHC CLASS I MOLECULE 
IN POOR PROGNOSIS BREAST CANCERS
Z Madjd , I Spendlove , SE Pinder , J Ronan , EC Paish , LG Durrant 
University of Nottingham, Nottingham, United Kingdom
Background: Tumours can be recognised by either CTL or NK cells.
CTL recognition depends on expression of MHC class I loaded with
peptides from tumour antigens. In contrast, loss of MHC class I would
result in NK activation. The aim of this study was to quantify HLA
class I expression in relation to breast tumour prognosis.   Methods:
A large set of samples (439) from patients with primary operable
invasive breast cancer with a mean follow up of 87 months were
evaluated for the expression of HLA ABC class I antigen, using
HC10 (HLA-ABC heavy chain) monoclonal antibody utilising tissue
microarrays. Expression was then compared with different prognostic
factors and outcome.   Results: Normal breast tissue adjacent to tumour
demonstrated high levels of expression of class-I antigens. In contrast,
206 out of 439 (47%) of breast carcinomas were considered negative for
HLA Class I expression, 45% (197) showed a reduction in the level of
expression and only 35 cases (8 %) expressed high levels of HLA class
I. We found a direct relationship between patient survival and HLA-
negative phenotype (p<0.05); as well as a positive association between
histological grade (p<0.001), distant metastasis (p<0.05), Nottingham
Prognostic Index (p<0.001), tumour type (p<0.05) and recurrence
(p<0.05) and the level of expression of HLA class I.   
Conclusion: Our results lead us to conclude that, unexpectedly, in this
large series of invasive breast cancers, down-regulation of HLA ABC was
more often found in low grade, good prognosis tumours compared to bad
prognosis cancers, also that patients with carcinomas exhibiting lower
levels of HLA ABC expression achieved longer survival times. These
results suggest that loss of MHC class I may result in NK activation
resulting a better tumour prognosis. Future studies will attempt to
examine the inﬁ  ltration of NK cells in this series of breast tumours.
8.3
NCOR1 IS FREQUENTLY ELEVATED IN BREAST CANCER 
CELLS; MOLECULAR AND CLINICAL SIGNIFICANCE
C.M. Banwell 1, S. Vaisanen 2, M. Guy 3, K.W. Colston 3, C. Carlberg 2, 
M.J. Campbell 1
1 Institute of Biomedical Research, University of Birmingham, 
Birmingham, United Kingdom, 2 Dept. of Biochemistry, University of 
Kuopio, Kuopio, Finland, 3 Dept. of Cellular and Molecular Medicine, 
St. George’s, London, United Kingdom
The vitamin D3 receptor (VDR) and other nuclear receptors regulate the 
transcription of antiproliferative target genes such as p21(waf1/cip1)  and 
control proliferation of normal breast epithelial cells. We proposed in 
cancer cells that altered activity of NCoR1 and other nuclear receptor co-
repressors sustains histone deacetylation (HDAC) activity at target gene 
promoters resulting in insensitivity to these actions. This can be overcome 
by co-treatments of nuclear receptor ligand (e.g. 1α,25(OH)2D3) plus HDAC 
inhibitors. Quantitative real time RT-PCR analyses revealed NCoR1 was 
frequently (13/19) elevated (>2 fold) in breast cancer cell lines compared to 
non-malignant MCF-12A cells. Similarly in a panel of matched tumour and 
normal samples we found highest elevation of NCoR1 in both ER+ve (11 
out of 20) and ER-ve (7 out of 16) tumours, with a mean 6.2 and 14.2 fold 
increase respectively. In both cell lines and tumour material levels of SMRT, 
a related co-repressor, was co-elevated in 10 samples. 
To dissect the molecular signiﬁ   cance of NCoR1 elevation we have 
undertaken comprehensive long range scanning (>10 kb upstream of the 
transcriptional start) of the  human p21(waf1/cip1)    promoter in MCF-7 cells 
by designing 26 over-lapping primer pairs combined with formaldehyde 
cross-linking chromatin immunoprecipitation (ChIP). This has allowed us to 
capture the spatial and temporal regulation (0-300 mins post treatment with 
1α,25(OH)2D3) of both the histone acetylation status and the interactions of 
NCoR1 and other proteins on the p21(waf1/cip1)  promoter. These studies have 
found the VDR and its heterodimeric partner retinoid X receptor bind to at 
least ﬁ  ve individual regions of the promoter.  This study demonstrates that 
it would be possible to monitor critical changes in the p21(waf1/cip1)  promoter 
in  response to multiple cancer-therapeutic agents such as nuclear receptor 
ligands, HDAC inhibitors,  genistein, and aromatase inhibitors.
8.4
ORAL IDARUBICIN AND ORAL CAPECITABINE IN THE 
TREATMENT OF LOCALLY ADVANCED OR ADVANCED BREAST 
CANCER – A DOSE FINDING STUDY
F Nussey 1, J Afseth 2, E Murray 2, A Bowman 2, R Leonard 3,
D Cameron 2
1 University of Edinburgh, Edinburgh, United Kingdom, 2 Edinburgh 
Cancer Centre, Edinburgh, United Kingdom, 3 South West Wales 
Cancer Institute, Swansea, United Kingdom
Introduction. Anthracyclines and 5 FU are widely used and effective drugs
for the treatment of breast cancer.  In advanced breast cancer response rates
of over 70% can be achieved using a schedule of weekly bolus adriamycin
and continuous infusional 5FU.  Many patients however prefer oral
chemotherapy, so we have developed an oral regimen using idarubicin and
the 5FU pro drug capecitabine.  
Materials and Methods.  30 post menopausal patients were recruited, 17
in the dose ﬁ  nding phase and 13 in the expansion phase.  The starting doses
were 10mg/m2 idarubicin days 1-3 and capecitabine 750mg/m2 days 1-14,
repeated every 21 days.  Doses were escalated as follows; 10/750 (n=6),
10/1000 (n=3), 10/1250 (n=5), 12.5/1000 (n=3), with the expansion phase at
10/1000 (n=12).  Patients were evaluated for toxicity with each cycle and for
response at cycles 3 and 6. 
Results.  The median age of patients was 66 (54 –76), and the mean number
of cycles dispensed was 5 (1-12). Two patients had chemo-naive locally
advanced breast carcinoma; the remainder received this regimen as ﬁ  rst
line chemotherapy for metastatic or locally recurrent disease.  There were
three deaths within 4 weeks of receiving trial medication, 2 attributable to
progressive disease and one related to haematological and treatment related
toxicity at the highest dose level.  The dose limiting toxicity was neutropenia
at 12.5/1000. In the dose ﬁ  nding phase there was one complete and 6 partial
physician reported responses. In the extension phase there were 2 complete
and 2 partial responses in 7 patients conﬁ  rmed by independent radiological
review to give a conﬁ  rmed response rate of 57%.
Conclusions. We believe that we have developed a feasible oral cytotoxic
regimen for the treatment of post-menopausal advanced breast carcinoma,
with encouraging evidence of disease activity.  The 10/1000 combination
requires further evaluation in a phase 2/3 setting.  
Gabra H, Cameron DA, et al. Br J Cancer. 1996 Dec;74(12):2008-12.
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UNCOVERING COMPLEX PATTERNS OF CPG ISLAND 
METHYLATION ASSOCIATED WITH CLINICAL OUTCOME IN 
OVARIAN CANCER
J.A Hall 1, J Paul 1, S.H Wei 2, T.H.M Huang 2, R Brown 1
1 Centre of Oncology and Applied Pharmacology, Glasgow University, 
Glasgow, United Kingdom, 2 Department of Molecular Virology, 
Immunology, and Medical Genetics, The Ohio State University, 
Columbus, United States
We aim to extract and prioritize information from complex methylation data 
to aid design and to direct chemotherapy for ovarian cancer. A supervised 
method of hierarchical clustering (Hastie, T, Tibshirani, R. et al. 2001, 
Genome Biol, 2, 3.1) was applied to uncover correlations between groups 
of CpG islands (CGI) and their synergistic interactions and an endpoint 
related to chemo-responsiveness of ovarian tumours. Groups of CGIs and 
their interactions may provide more robust indicators of clinical outcome 
than individual CGIs.
We developed a program to apply tree harvesting to data from Differential 
Methylation Hybridisation (Wei, S.H., Chen, C.M. et al. 2002 Clin Cancer 
Res, 8, 2246), a micro-array based method for assessing methylation. Data 
was collected from 948 CGI in 18 tumour samples with known patient 
progression free survival (pfs). Hierarchical clustering of the 948 CGI 
(distance: Pearson’s correlation coefﬁ   cient, method: complete linkage) 
divided the dataset into (2x948) -1 clusters. All unique average gene proﬁ  les 
of clusters and two-way interactions of proﬁ  les with terms already in the 
regression model were entered into Cox regression analysis using pfs as the 
outcome measure. Single CGIs were considered alongside groups of CGIs. 
The best model in terms of ﬁ  t and predictive ability was selected using a 
score statistic.
Initial results suggest a single CGI and a group of eight CGIs are associated 
with pfs (p = 0.0006, p = 0.003 respectively), on cross validation the single 
CGI is selected as the best predictor (p = 0.021). 
Identifying single CGIs and groups of CGI may provide insight into 
coordinated methylation of multiple CGIs involved in drug resistance, and 
aid prediction of patient response to chemotherapy but careful validation of 
results is required to assess the robustness of complex associations.
8.6
CHEMODENSE CISPLATIN AND ORAL ETOPOSIDE 
TREATMENT IN RELAPSED OVARIAN CANCER
WA Verborg , LR Campbell , MS Highley , EM Rankin 
Division of Cancer Medicine, Ninewells Hospital, Dundee,
United Kingdom
Introduction: The optimal treatment of relapsing or progressive ovarian
cancer after initial platinum-based therapy remains a challenge. Treatment
of platinum-resistant disease (relapse <6 m) is controversial. A weekly
chemodense regimen combining cisplatin and etoposide has reported
activity in this group (Van der Burg et al, British Journal of Cancer (2002)
86, 19-25). We retrospectively reviewed the experience with this regimen in
our institution. Methods: 33 patients with recurrent or progressive bulky
stage IIIc/IV ovarian cancer were treated. Cisplatin (50mg/m2) in normal
saline  was given weekly, weeks 1-3 and 5-7, combined with oral etoposide
(50mg daily, days 1-15 and 29-43). Responders and those with stable disease,
assessed by Ca125 and imaging, were then commenced on maintenance oral
etoposide therapy (50mg daily for 21 days out of 28) for 6-9 cycles, or until
disease progression. Results: The ﬁ  rst 26 patients have now been analysed.
All patients had previously received carboplatin and a taxane. The median
number of prior regimens was 1 (range 1-3). The platinum-free interval (PFI)
was < 6 months in 10 patients, 6-12 months in 8 patients and >12 months
in 8 patients. Following induction therapy, the overall radiological response
rate (CR+PR) was 64% (95% CI 43-81%), stable disease 36% and CA125
response rate 96% (95% CI 79-99%). The cisplatin/etoposide induction
phase was well tolerated. Grade 3/4 toxicity experienced: leucopenia 35%,
fatigue 10%, neutropenic fever 15%, nausea and vomiting 5%. A median of
5 cycles (range 1-15) of maintenance etoposide was given and toxicity was
minimal. Overall median survival was 16.5 m. Median survival was 10.5
m in the platinum-resistant group, 17.5 m  in those with a platinum-free
interval of 6-12 m and 18.5 m in those with a platinum-free interval >12 m.
Median progression free interval on imaging was 9 m. Conclusion: Weekly
cisplatin/etoposide, followed by maintenance oral etoposide, is an active and
well tolerated regimen in relapsed or progressive ovarian cancer, even in
platinum-resistant patients.
8.7
IS 10-YEAR FOLLOW UP OF OVARIAN CANCER WORTHWHILE?
F Azribi , M Mackean , M Stewart , J.F Smyth 
Edinburgh Cancer Centre,Western General Hospital, Edinburgh, 
United Kingdom
Objective: To determine long-term survival and predictors of recurrence 
in patients with ovarian cancer who survived over 5 years.
Design: The Database (from January 1984 to December 1998) was 
reviewed with 372 ovarian cancer patients who had survived relapse 
free for over 5 years.  30 patients have since relapsed (8.1%).  Case notes 
were examined for prognostic factors and results of relapse.
Results:
Follow up: Median period of follow up 10 years (Max 19.6 yrs).
Mode of detection: Of the 30 patients who relapsed, 7 were discovered 
on routine follow up with a positive yield of follow-up of 0.018%. 12 
were referred by GP, 4 were self-referrals, 3 were an incidental ﬁ  nding 
at another medical specialty, and 4 no available information. 11, 9 and 
6 patients relapsed in year 5, 6 and 7 respectively.  The median age for 
relapsed was 56 (range 23-81).
Survival 5 patients are still alive post relapse. Median survival post 
relapse = 19.1 months (95% Conﬁ  dence interval 13.3 -28.1 months).   
Positive predictors for relapse at 5 years were advanced stage 
(p=0.0001), serous pathology (p=0.0001) and high grade of tumour 
(p=0.026).  Negative predictors were age, performance status, CA 125 
at presentation, serum albumin, and alkaline phosphatase levels.
Conclusion: Ovarian cancer patients who survive over 5 years have 
excellent long-term survival rates. The predictors for relapse at 5 
years are no different from those at initial presentation.  Is the annual
review at Oncology clinics the best way to detect the relapse, and cost-
effective?
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